サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1606458

胃不全麻痺治療市場：薬剤クラス別、タイプ別、投与経路別、適応疾患別、流通経路別、国別、地域別：産業分析、市場規模、市場シェア、2024年～2032年予測

Gastroparesis Treatment Market, By Drug Class, By Type, By Route of Administration, By Disease Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 311 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
胃不全麻痺治療市場：薬剤クラス別、タイプ別、投与経路別、適応疾患別、流通経路別、国別、地域別：産業分析、市場規模、市場シェア、2024年～2032年予測
出版日: 2024年11月04日
発行: AnalystView Market Insights
ページ情報: 英文 311 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートのハイライト

胃不全麻痺治療市場規模は2023年に63億9,043万となり、2024年から2032年にかけてCAGR 4.77%で拡大します。

胃不全麻痺治療市場 - 市場力学

世界の糖尿病有病率の増加が市場需要を促進

糖尿病は胃不全麻痺の主な原因であるため、世界の糖尿病患者の増加が胃不全麻痺への需要を促進しています。国際糖尿病連盟の報告によると、2021年には5億3,700万人の成人が糖尿病を患っており、2030年には6億4,300万人に増加すると予測されています。また、胃不全麻痺は高齢者に多く、世界の高齢化人口の増加が胃不全麻痺治療の需要を支えています。しかし、現在の胃不全麻痺治療は、症状を治すことよりも症状の管理に重点を置いているため、効果が限定的で患者の不満足につながっています。これが今後数年間の市場成長の妨げになる可能性があります。その一方で、胃不全麻痺の根本的な原因に関する継続的な調査、啓発キャンペーンの増加、早期発見を改善するための診断ツールの進歩はすべて、予測期間中に世界の胃不全麻痺治療市場に大きな成長機会をもたらすと期待されています。

胃不全麻痺治療市場 - 主要インサイト

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024～2032年）に約4.77％のCAGRで毎年成長すると推定されます。

薬剤クラス別では、プロキネティック薬が2023年に最大市場シェアを示すと予測されます。

タイプ別では、処方薬が2023年の主要セグメントでした。

投与経路別では、経口薬が2023年の主要セグメントでした。

適応疾患別では、糖尿病性胃不全麻痺が2023年の主要セグメントでした。

流通チャネル別では、病院薬局が2023年の主要セグメントでした。

地域別では、北米胃不全麻痺治療市場が2023年の主要収益源でした。

胃不全麻痺治療市場 - セグメンテーション分析：

胃不全麻痺治療の世界市場は薬剤クラス別、タイプ別、投与経路別、適応疾患別、流通チャネル別、地域別に区分されます。

薬剤クラス別では、制吐剤、プロキネティック剤、プロトンポンプ阻害剤、その他の4つに分類されます。運動促進剤は胃の筋収縮を促進し、吐き気などの症状を緩和し、消化を改善するため、胃不全麻痺の治療において極めて重要です。その有効性は胃不全麻痺にとどまらず、経腸栄養を受けている重症患者にも役立ち、摂食不耐性を軽減することが研究で示されています。

世界の胃不全麻痺治療市場は、種類によって処方薬と市販薬の2つに分類されます。予測期間中は、処方薬部門が市場を独占する可能性が高いです。これは、胃不全麻痺の有病率が上昇し、効果的な治療に対する需要が高まっているためです。処方薬は多くの場合、より強力で、症状の複雑さに対処するために特別に調整されており、ヘルスケアプロバイダーや患者の間でそれらの採用を推進しています。

胃不全麻痺治療市場 - 地理的洞察

地理的には、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東アフリカの地域に広がっています。これらの地域は、ビジネスをもたらす国ごとにさらに分割されます。

胃不全麻痺治療市場 - 競合情勢：

胃不全麻痺の有病率の増加は、革新的な治療オプションに焦点を当てた競合情勢を作り出しています。企業は、運動促進剤や食事管理ソリューションを含む先進的な治療法を導入するための研究開発を優先しています。ヘルスケア専門家や研究機関との連携は、治療効果を高め、最新の臨床手法の採用を促進しています。さらに、早期診断と患者の治療へのアドヒアランスを向上させるためには、教育的取り組みを通じて認識を高めることが不可欠です。個別化医療の動向も台頭しており、個々の患者のニーズによりよく対応したオーダーメイドの治療計画が可能となっています。

目次

第1章 胃不全麻痺治療市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 胃不全麻痺治療の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 胃不全麻痺治療産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 胃不全麻痺治療市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 胃不全麻痺治療市場情勢

  • 胃不全麻痺治療市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 胃不全麻痺治療市場：薬剤クラス別

  • 概要
    • 薬剤クラス別セグメントシェア分析
    • 制吐剤
    • プロキネティック剤
    • プロトンポンプ阻害剤
    • その他

第8章 胃不全麻痺治療市場：タイプ別

  • 概要
    • タイプ別セグメントシェア分析
    • 処方薬
    • 市販薬

第9章 胃不全麻痺治療市場：投与経路別

  • 概要
    • 投与経路別セグメントシェア分析
    • 鼻腔
    • 注射剤
    • 経口

第10章 胃不全麻痺治療市場：適応疾患別

  • 概要
    • 適応疾患別セグメントシェア分析
    • 特発性胃不全麻痺
    • 糖尿病性胃不全麻痺
    • 術後胃不全麻痺

第11章 胃不全麻痺治療市場：流通チャネル別

  • 概要
    • 流通チャネル別セグメントシェア分析
    • オンライン薬局
    • 小売薬局
    • 病院薬局

第12章 胃不全麻痺治療市場：地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析- 胃不全麻痺治療業界

  • 競合ダッシュボード
    • Competitive Benchmarking
    • Competitive Positioning
  • 企業プロファイル
    • Medtronic plc
    • Abbott Laboratories
    • Salix Pharmaceuticals, Inc.
    • Kimberly-Clark Corporation
    • CR Bard, Inc
    • Boston Scientific Corporation
    • Janssen Global Services LLC
    • Alfa Wassermann SPA
    • AbbVie Inc.
    • Evoke Pharma
    • Cardinal Health, Inc.
    • Rhythm Pharmaceuticals, Inc.
    • GlaxoSmithKline Plc
    • Bausch Health
    • Neurogastrx, Inc.
    • Theravance Biopharma
    • AstraZeneca Plc
    • Cipla Limited
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Limited
    • The Takeda Pharmaceutical Company Ltd.
    • Processa Pharmaceuticals, Inc.
    • Vanda Pharmaceuticals, Inc.
    • Otsuka Holdings Co. Ltd.
    • ANI Pharmaceuticals, Inc.
    • CinDome Pharma, Inc.
    • PTC Therapeutics
    • Ironwood Pharmaceuticals, Inc.
    • Others

第14章 アナリストの全方位展望

目次
Product Code: ANV4173

REPORT HIGHLIGHT

Gastroparesis treatment market size was valued at USD 6,390.43 Million in 2023, expanding at a CAGR of 4.77% from 2024 to 2032.

Gastroparesis is a condition in which the stomach's ability to empty is delayed due to partial paralysis. This causes food to remain in the stomach longer than normal. The gastroparesis treatment focuses on managing delayed stomach emptying, aiming to alleviate symptoms like nausea, vomiting, and bloating. Primary approaches include prokinetic agents that enhance gastric motility, antiemetics to control nausea, and dietary modifications for symptom relief. For severe cases, gastric electrical stimulation may be used. As gastroparesis is commonly linked to diabetes and is often underdiagnosed, early diagnosis and targeted treatments are essential for effective management.

Gastroparesis Treatment Market- Market Dynamics

Increasing prevalence of diabetes globally to propel market demand

As diabetes is a major cause of gastroparesis, the global increase in diabetes cases fuels demand for gastroparesis treatments. The International Diabetes Federation reports that 537 million adults were living with diabetes in 2021, with numbers projected to rise to 643 million by 2030. Besides, as gastroparesis is more common in older adults, the global increase in the aging population supports demand for gastroparesis treatment. However, current gastroparesis treatments focus on symptom management rather than curing the condition, which limits effectiveness and leads to patient dissatisfaction. This may hamper the market growth in the coming years. On the contrary, ongoing research into the underlying causes of gastroparesis, increasing awareness campaigns, and advancements in diagnostic tools to improve early detection are all expected to provide massive growth opportunities for the global gastroparesis treatment market during the forecast period.

Gastroparesis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.77% over the forecast period (2024-2032)

Based on drug class segmentation, prokinetic drugs was predicted to show maximum market share in the year 2023

Based on type segmentation, prescription drugs was the leading segment in 2023

Based on route of administration segmentation, oral was the leading type in 2023

Based on disease indication segmentation, diabetes gastroparesis was the leading segment in 2023

Based on distribution channel segmentation, hospital pharmacies was the leading segment in 2023

On the basis of region, the North America gastroparesis treatment market was the leading revenue generator in 2023

Gastroparesis Treatment Market- Segmentation Analysis:

The Global Gastroparesis Treatment Market is segmented on the basis of Drug Class, Type, Route of Administration, Disease Indication, Distribution Channel, and Region.

The market is divided into four categories based on drug class: antiemetic drugs, prokinetic agents, proton pump inhibitors, and others. Prokinetic agents are crucial in the treatment of gastroparesis as they enhance stomach muscle contractions, alleviating symptoms like nausea and improving digestion. Their effectiveness extends beyond gastroparesis and studies have shown that they also help critical patients receiving enteral nutrition, reducing feeding intolerance.

The global gastroparesis treatment market is divided into two categories based on type: prescription drugs and over-the-counter drugs. The prescription drugs sector is likely to dominate the market during the forecast period. This is due to the rising prevalence of gastroparesis and the growing demand for effective treatments. Prescription medications are often more potent and specifically tailored to address the complexities of the condition, which drives their adoption among healthcare providers and patients.

Gastroparesis Treatment Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Gastroparesis Treatment Market- Competitive Landscape:

The increasing prevalence of gastroparesis is creating a competitive landscape focused on innovative treatment options. Companies are prioritizing research and development to introduce advanced therapies, including prokinetic agents and dietary management solutions. Collaborations with healthcare professionals and research institutions enhance treatment effectiveness and foster the adoption of the latest clinical practices. Additionally, raising awareness through educational initiatives is essential for improving early diagnosis and patient adherence to treatments. The trend towards personalized medicine is also emerging, allowing for tailored treatment plans that better address individual patient needs.

Recent Developments:

In June 2024, Renexxion Ireland Limited, a biopharmaceutical company focused on gastrointestinal treatments, has gained FDA approval for its Investigational New Drug application for naronapride. This oral drug targets gastroparesis, a disorder causing delayed stomach emptying with symptoms like nausea and vomiting, affecting millions in the U.S., Europe, and Australia.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GASTROPARESIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Medtronic plc
  • Abbott Laboratories
  • Salix Pharmaceuticals, Inc.
  • Kimberly-Clark Corporation
  • C. R. Bard, Inc
  • Boston Scientific Corporation
  • Janssen Global Services LLC
  • Alfa Wassermann SPA
  • AbbVie Inc.
  • Evoke Pharma
  • Cardinal Health, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Bausch Health
  • Neurogastrx, Inc.
  • Theravance Biopharma
  • AstraZeneca Plc
  • Cipla Limited
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Limited
  • The Takeda Pharmaceutical Company Ltd.
  • Processa Pharmaceuticals, Inc.
  • Vanda Pharmaceuticals, Inc.
  • Otsuka Holdings Co. Ltd.
  • ANI Pharmaceuticals, Inc.
  • CinDome Pharma, Inc.
  • PTC Therapeutics
  • Ironwood Pharmaceuticals, Inc.
  • Others

GLOBAL GASTROPARESIS TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Antiemetic Drugs
  • Prokinetic Agents
  • Proton Pump Inhibitors
  • Others

GLOBAL GASTROPARESIS TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Prescription Drugs
  • Over-the-Counter Drugs

GLOBAL GASTROPARESIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Nasal
  • Injectables
  • Oral

GLOBAL GASTROPARESIS TREATMENT MARKET, BY DISEASE INDIATION- MARKET ANALYSIS, 2019 - 2032

  • Idiopathic Gastroparesis
  • Diabetes Gastroparesis
  • Post-surgical Gastroparesis

GLOBAL GASTROPARESIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

GLOBAL GASTROPARESIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Gastroparesis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Gastroparesis Treatment Market Snippet by Drug Class
    • 2.1.2. Gastroparesis Treatment Market Snippet by Type
    • 2.1.3. Gastroparesis Treatment Market Snippet by Route of Administration
    • 2.1.4. Gastroparesis Treatment Market Snippet by Disease Indication
    • 2.1.5. Gastroparesis Treatment Market Snippet by Distribution Channel
    • 2.1.6. Gastroparesis Treatment Market Snippet by Country
    • 2.1.7. Gastroparesis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Gastroparesis Treatment Key Market Trends

  • 3.1. Gastroparesis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Gastroparesis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Gastroparesis Treatment Market Opportunities
  • 3.4. Gastroparesis Treatment Market Future Trends

4. Gastroparesis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Gastroparesis Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Gastroparesis Treatment Market Landscape

  • 6.1. Gastroparesis Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Gastroparesis Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Antiemetic Drugs
    • 7.1.3. Prokinetic Agents
    • 7.1.4. Proton Pump Inhibitors
    • 7.1.5. Others

8. Gastroparesis Treatment Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 8.1.2. Prescription Drugs
    • 8.1.3. Over-the-Counter Drugs

9. Gastroparesis Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Nasal
    • 9.1.3. Injectables
    • 9.1.4. Oral

10. Gastroparesis Treatment Market - By Disease Indication

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Disease Indication, 2023 & 2032 (%)
    • 10.1.2. Idiopathic Gastroparesis
    • 10.1.3. Diabetes Gastroparesis
    • 10.1.4. Post-surgical Gastroparesis

11. Gastroparesis Treatment Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Online Pharmacies
    • 11.1.3. Retail Pharmacies
    • 11.1.4. Hospital Pharmacies

12. Gastroparesis Treatment Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Gastroparesis Treatment Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Gastroparesis Treatment Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Gastroparesis Treatment Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Gastroparesis Treatment Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Gastroparesis Treatment Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Gastroparesis Treatment Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Medtronic plc
    • 13.2.2. Abbott Laboratories
    • 13.2.3. Salix Pharmaceuticals, Inc.
    • 13.2.4. Kimberly-Clark Corporation
    • 13.2.5. C. R. Bard, Inc
    • 13.2.6. Boston Scientific Corporation
    • 13.2.7. Janssen Global Services LLC
    • 13.2.8. Alfa Wassermann SPA
    • 13.2.9. AbbVie Inc.
    • 13.2.10. Evoke Pharma
    • 13.2.11. Cardinal Health, Inc.
    • 13.2.12. Rhythm Pharmaceuticals, Inc.
    • 13.2.13. GlaxoSmithKline Plc
    • 13.2.14. Bausch Health
    • 13.2.15. Neurogastrx, Inc.
    • 13.2.16. Theravance Biopharma
    • 13.2.17. AstraZeneca Plc
    • 13.2.18. Cipla Limited
    • 13.2.19. Pfizer, Inc.
    • 13.2.20. Teva Pharmaceutical Industries Limited
    • 13.2.21. The Takeda Pharmaceutical Company Ltd.
    • 13.2.22. Processa Pharmaceuticals, Inc.
    • 13.2.23. Vanda Pharmaceuticals, Inc.
    • 13.2.24. Otsuka Holdings Co. Ltd.
    • 13.2.25. ANI Pharmaceuticals, Inc.
    • 13.2.26. CinDome Pharma, Inc.
    • 13.2.27. PTC Therapeutics
    • 13.2.28. Ironwood Pharmaceuticals, Inc.
    • 13.2.29. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us